Russell Investments Group
BCRX icon

Russell Investments Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Russell Investments Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$747K Sell
74,699
-196,969
-73% -$1.78M ﹤0.01% 2604
2026
Q1 		$2.59M Buy
271,668
+42,442
+19% +$330K ﹤0.01% 1727
2025
Q4 		$1.79M Sell
229,226
-85,267
-27% -$616K ﹤0.01% 1934
2025
Q3 		$2.39M Sell
314,493
-125,756
-29% -$1.05M ﹤0.01% 1765
2025
Q2 		$3.94M Buy
440,249
+336,920
+326% +$3.14M 0.01% 1358
2025
Q1 		$775K Buy
103,329
+75,363
+269% +$608K ﹤0.01% 2139
2024
Q4 		$210K Buy
27,966
+12,941
+86% +$98.2K ﹤0.01% 2528
2024
Q3 		$114K Sell
15,025
-68,228
-82% -$519K ﹤0.01% 2629
2024
Q2 		$515K Buy
83,253
+24,528
+42% +$135K ﹤0.01% 2187
2024
Q1 		$298K Buy
58,725
+39,205
+201% +$220K ﹤0.01% 2362
2023
Q4 		$117K Sell
19,520
-1,239
-6% -$7.18K ﹤0.01% 2531
2023
Q3 		$147K Sell
20,759
-27,921
-57% -$201K ﹤0.01% 2546
2023
Q2 		$343K Sell
48,680
-123,485
-72% -$991K ﹤0.01% 2339
2023
Q1 		$1.44M Buy
172,165
+21,172
+14% +$204K ﹤0.01% 1771
2022
Q4 		$1.73M Buy
150,993
+23,818
+19% +$297K ﹤0.01% 1682
2022
Q3 		$1.6M Sell
127,175
-120,347
-49% -$1.55M ﹤0.01% 1673
2022
Q2 		$2.62M Buy
247,522
+167,096
+208% +$1.72M 0.01% 1441
2022
Q1 		$1.31M Buy
80,426
+78,363
+3,798% +$1.26M ﹤0.01% 1832
2021
Q4 		$28K Hold
2,063
– – ﹤0.01% 2935
2021
Q3 		$29K Buy
+2,063
New +$32.5K ﹤0.01% 2977
2020
Q2 		– Sell
-161,807
Closed -$323K – 3127
2020
Q1 		$323K Sell
161,807
-172,918
-52% -$476K ﹤0.01% 2361
2019
Q4 		$1.15M Buy
334,725
+172,180
+106% +$433K ﹤0.01% 2034
2019
Q3 		$466K Buy
+162,545
New +$506K ﹤0.01% 2317
2017
Q3 		– Sell
-13,373
Closed -$74K – 2944
2017
Q2 		$74K Sell
13,373
-36,265
-73% -$221K ﹤0.01% 2839
2017
Q1 		$417K Buy
49,638
+33,438
+206% +$233K ﹤0.01% 2490
2016
Q4 		$104K Buy
+16,200
New +$84.3K ﹤0.01% 2864

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Russell Investments Group's BCRX Position: Q2 2026 in Review

Russell Investments Group reduced its BioCryst Pharmaceuticals (BCRX) stake by 73% in Q2 2026, selling an estimated $1.78M and leaving 74,699 shares worth $747K. The position accounts for ﹤0.01% of the portfolio, ranked #2604.

Russell Investments Group first reported a position in BCRX in Q4 2016 and has held it in 26 quarters since. The position peaked at $3.94M in Q2 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Russell Investments Group held 74,699 shares of BioCryst Pharmaceuticals worth $747K as of Q2 2026.
  • Russell Investments Group sold 196,969 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.78M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2604 holding.
  • Russell Investments Group first reported a position in BioCryst Pharmaceuticals in Q4 2016 and has held it in 26 quarters since.
  • Russell Investments Group's BioCryst Pharmaceuticals position peaked at $3.94M in Q2 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.